Background: Prospective studies examining long-term therapeutic outcomes of the BIC+FTC+TAF regimen in human immunodeficiency virus (HIV) infection remain limited. This study assessed the actual efficacy and safety of BIC+FTC+TAF in HIV-infected individuals in southwest China.
Methods: This was a single-center, prospective study enrolling treatment-naïve (n=32) and treatment-experienced (n=177) HIV-infected patients administered BIC+FTC+TAF treatment between March 2022 and August 2022. The data were collected until February 28, 2023. Virological reactions and adverse events to the treatment were recorded, and patient subjective feelings in the form of ePRO were collected. The primary endpoint was the rate of patients with HIV viral load <50 copies/mL at week 24.
Results: At week 24, 87.5% and 95.5% of treatment-naïve and treatment-experienced HIV patients had a viral load <50 copies/mL, respectively. CD4 cell counts in treatment-naïve and treatment-experienced patients increased significantly by 163.5 cells/μL (P=0.002) and 55.0 cells/μL (P=0.022), respectively. By week 24, no patients had discontinued the BIC+FTC+TAF treatment due to adverse events. Based on ePRO data, treatment-naïve and treatment-experienced patients at week 24 had stable disease symptom burden, quality of life, and depression level after treatment with BIC+FTC+TAF.
Conclusion: BIC+FTC+TAF reduces the viral load in treatment-naïve patients with high viral load as well as treatment-experienced patients with residual viremia. The patient's subjective experience was maintained stable after treatment with BIC+FTC+TAF. This study also revealed a very low incidence for BIC+FTC+TAF drug-related side effects.
Background
To evaluate the therapeutic effect and tolerance of BIC/FTC/TAF used for 24-week in ART-naïve in China.
Methods
This single-center retrospective cohort study included ART-naïve who received BIC/FTC/TAF from July 2021 to April 2022. The proportion of patients with HIV RNA < 50 cp/ml at the end point of 24-week (virological inhibition rate) was the primary outcome, and the changes of CD4 cell count, CD4/CD8, weight, blood lipid, and safety were secondary outcomes.
Results
A total of 80 ART-naïve were enrolled. The inhibition rate of virology was 86.3% 24-week. The median CD4 cell count increased from 212 cells/µL (90.3-398.3) at baseline to 348 cells/µL (219.8–541.0) at 24-week. The median CD4/CD8 ratio increased from 0.25 (0.13–0.37) at baseline to 0.40 (0.26–0.66) at 24-week. During the follow-up of 80 ART-naïve using BIC/FTC/TAF, 16 patients had adverse events; however, no drug withdrawal was caused by adverse events.
Conclusion
This real-world cohort study showed that BIC/FTC/TAF could achieve good immunological and virological responses in ART-naïve. In addition, this study also shows good safety.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.